Anal Sac Adenocarcinoma

Anal sac adenocarcinoma (ASAC) is a malignant neoplasm arising from the apocrine glands of the anal sacs, most commonly affecting dogs. These tumors are locally invasive, frequently metastasize to regional lymph nodes (especially the iliosacral lymph nodes), and are often associated with paraneoplastic hypercalcemia due to the secretion of parathyroid hormone-related protein (PTHrP). The disease is characterized by a palpable mass in the perianal region, tenesmus, dyschezia, and systemic signs related to hypercalcemia, such as polyuria, polydipsia, and lethargy. Surgical excision (anal sacculectomy) remains the primary treatment, often combined with lymph node extirpation and adjunctive chemotherapy or radiation therapy for advanced disease. The tumor is graded based on histological features and clinical stage, with prognosis influenced by tumor size, lymph node metastasis, and hypercalcemia at presentation.

The exact etiology of anal sac adenocarcinoma is unknown, but it is believed to arise from spontaneous neoplastic transformation of apocrine glandular epithelial cells within the anal sacs. Chronic inflammation of the anal sacs (anal sacculitis) has been proposed as a potential predisposing factor, although a direct causal relationship has not been established. Genetic predisposition is suggested by the higher incidence in certain breeds, such as English Cocker Spaniels, Springer Spaniels, and German Shepherds, indicating a possible hereditary component. Hormonal influences may play a role, as the apocrine glands are hormonally responsive, but no specific endocrine trigger has been identified. Environmental factors, including diet and exposure to carcinogens, have not been conclusively linked to the development of ASAC. The tumor's molecular pathogenesis involves dysregulation of cell cycle control, apoptosis, and angiogenesis, with overexpression of growth factors and their receptors, such as EGFR and VEGF, contributing to tumor progression and metastasis.

Anal sac adenocarcinoma is an uncommon neoplasm, accounting for approximately 2% of all skin tumors and 17% of perianal tumors in dogs. It is rare in cats, with only sporadic case reports. The disease predominantly affects older dogs, with a median age of 10 years (range 6-15 years). There is a slight female predisposition, with a female-to-male ratio of approximately 1.5:1. Breed predispositions include English Cocker Spaniels, Springer Spaniels, German Shepherds, and mixed-breed dogs. No significant sex predilection has been noted in cats. The tumor is locally aggressive, with a high metastatic rate to regional lymph nodes (iliosacral, sublumbar, and inguinal) at the time of diagnosis, reported in 40-80% of cases. Distant metastasis to lungs, liver, and bone occurs less frequently but is more common in advanced stages. The incidence of paraneoplastic hypercalcemia at presentation ranges from 25% to 50%, and it is associated with a poorer prognosis.

Anal sac adenocarcinoma originates from the apocrine glands of the anal sac wall. The tumor grows locally, invading surrounding tissues including the anal sphincter, rectum, and perianal skin. Histologically, it is characterized by acinar or tubular structures lined by cuboidal to columnar epithelial cells with varying degrees of atypia and mitotic activity. The tumor secretes parathyroid hormone-related protein (PTHrP), which binds to PTH receptors in bone and kidney, leading to increased osteoclastic bone resorption, increased renal tubular calcium reabsorption, and decreased renal phosphate reabsorption, resulting in hypercalcemia and hypophosphatemia. Chronic hypercalcemia can cause nephrogenic diabetes insipidus, leading to polyuria and polydipsia, and can progress to nephrocalcinosis and renal failure. Metastasis occurs primarily via lymphatic invasion to the iliosacral lymph nodes, which can become markedly enlarged and may cause tenesmus or constipation due to compression of the rectum. Hematogenous spread to lungs and other organs occurs in later stages. The tumor's growth and metastasis are influenced by angiogenesis, with vascular endothelial growth factor (VEGF) expression correlating with tumor aggressiveness.

Predisposing factors for anal sac adenocarcinoma include breed predisposition, particularly in English Cocker Spaniels, Springer Spaniels, and German Shepherds, suggesting a genetic component. Age is a significant factor, with older dogs (median 10 years) being more commonly affected. Female dogs may be at slightly higher risk. Chronic anal sac disease, such as recurrent anal sacculitis or impaction, has been proposed as a potential risk factor, although evidence is inconclusive. Obesity and a high-fat diet may increase the risk of anal sac disorders, but their direct link to adenocarcinoma is not established. Prior history of perianal tumors or other malignancies may also increase risk. Immunosuppression, either due to age or concurrent disease, could potentially contribute to tumor development. Environmental factors, such as exposure to certain chemicals or toxins, have not been identified as significant risk factors.

Clinical signs of anal sac adenocarcinoma vary depending on tumor size, local invasion, and presence of metastasis or hypercalcemia. Common signs include a palpable perianal mass, often detected incidentally during routine examination or grooming. As the tumor grows, it may cause tenesmus, dyschezia, constipation, and ribbon-like stools due to rectal compression. Pain on defecation and licking or biting at the perianal region may be observed. In cases with significant lymph node metastasis, a sublumbar mass may be palpable on abdominal palpation, and tenesmus may worsen. Paraneoplastic hypercalcemia manifests as polyuria, polydipsia, lethargy, weakness, anorexia, and vomiting. In advanced stages, weight loss, anemia, and signs of respiratory distress may occur due to pulmonary metastasis. On physical examination, a firm, irregular mass is palpable in the anal sac region, and the anal sac may be enlarged and painful. Digital rectal examination is essential to assess the extent of the mass and to palpate for sublumbar lymphadenopathy.

Differential diagnoses for anal sac adenocarcinoma include: 1) Anal sac impaction or abscess: presents with perianal swelling and pain, but lacks a discrete mass and is typically responsive to expression or drainage. 2) Perianal adenoma (hepatoid gland adenoma): benign, hormone-dependent tumor, more common in intact male dogs, often multiple, and does not metastasize. 3) Perianal adenocarcinoma (hepatoid gland adenocarcinoma): malignant, locally invasive, and can metastasize, but arises from hepatoid glands, not anal sac apocrine glands. 4) Anal sac adenoma: benign tumor of apocrine glands, rare, and does not invade or metastasize. 5) Squamous cell carcinoma of the perianal region: arises from the skin or anal canal, may be ulcerative, and has different histologic features. 6) Lymphoma of the perianal region: can present as a soft tissue mass, but is typically more diffuse and associated with systemic signs. 7) Perianal fistula: chronic inflammatory condition with draining tracts, but no discrete mass. 8) Rectal polyp or leiomyoma: intraluminal mass, may cause similar signs, but is located in the rectum rather than the anal sac. 9) Metastatic neoplasia from other sites: rare, but should be considered if there is a history of other cancers. Definitive diagnosis requires cytology or histopathology.

The diagnostic algorithm for anal sac adenocarcinoma begins with a thorough history and physical examination, including digital rectal palpation to assess the perianal region and sublumbar lymph nodes. If a mass is detected, fine-needle aspiration (FNA) of the mass and any enlarged lymph nodes should be performed for cytology. Cytology may reveal clusters of epithelial cells with anisocytosis and anisokaryosis, consistent with carcinoma. Baseline blood work, including serum biochemistry, should be performed to evaluate for hypercalcemia (elevated total calcium, ionized calcium) and renal function. Thoracic radiographs (three views) are recommended to screen for pulmonary metastasis. Abdominal ultrasonography is essential to evaluate the sublumbar lymph nodes and other abdominal organs for metastasis. If lymphadenopathy is detected, ultrasound-guided FNA of the affected lymph nodes is indicated. Advanced imaging, such as computed tomography (CT), may be beneficial for surgical planning, especially to assess the extent of local invasion and lymph node involvement. Definitive diagnosis requires histopathology of the excised tumor or a biopsy sample. Staging should be performed according to the WHO TNM system, with T (tumor size and invasion), N (lymph node metastasis), and M (distant metastasis) categories.

Laboratory findings in anal sac adenocarcinoma often reflect paraneoplastic hypercalcemia. Serum biochemistry may reveal hypercalcemia (total calcium > 11.5 mg/dL) and hypophosphatemia. Ionized calcium is the most accurate measure and should be assessed if available. Renal parameters (BUN, creatinine) may be elevated if hypercalcemia has caused renal damage. Urinalysis may show low urine specific gravity (isosthenuria) due to nephrogenic diabetes insipidus. Complete blood count may be normal, but anemia may be present in chronic disease. Coagulation panel (PT/aPTT) is typically normal, but should be assessed preoperatively. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated. Parathyroid hormone-related protein (PTHrP) levels can be measured and are often elevated in hypercalcemic patients. Histopathology of the tumor is essential for grading and assessing mitotic index, which has prognostic significance.

Radiography: Thoracic radiographs (right lateral, left lateral, and ventrodorsal views) are essential to detect pulmonary metastasis, which appears as nodular interstitial patterns. Abdominal radiographs may reveal a soft tissue mass in the perianal region or sublumbar lymphadenopathy, but are less sensitive than ultrasound. Ultrasonography: Abdominal ultrasound is highly sensitive for detecting sublumbar lymph node enlargement (iliosacral lymph nodes) and assessing the primary tumor's extent. Ultrasound-guided FNA of lymph nodes can confirm metastasis. Computed Tomography (CT): CT provides detailed cross-sectional imaging of the perianal region, allowing precise assessment of tumor size, invasion into surrounding tissues (anal sphincter, rectum), and lymph node involvement. CT is particularly useful for surgical planning and for radiation therapy planning. Magnetic Resonance Imaging (MRI): MRI offers superior soft tissue contrast and may be used to evaluate local invasion, but is less commonly used than CT. Fluoroscopy: Not typically used for this disease. Angiography: Not indicated.

Cytology: Fine-needle aspiration of the anal sac mass typically yields clusters of epithelial cells with moderate to marked anisocytosis, anisokaryosis, and prominent nucleoli. The cells may form acinar structures. Cytology of enlarged lymph nodes may reveal similar malignant epithelial cells, confirming metastasis. Histopathology: The tumor is composed of acinar or tubular structures lined by cuboidal to columnar epithelial cells with eosinophilic cytoplasm. Nuclear atypia, mitotic figures, and invasion into surrounding stroma are common. Histologic grading (based on mitotic count, nuclear pleomorphism, and necrosis) may have prognostic value. Immunohistochemistry can be used to confirm the apocrine origin (positive for cytokeratin, negative for vimentin). Surgical margins should be evaluated for completeness of excision. The presence of lymphatic invasion is associated with a higher risk of metastasis.

Treatment of anal sac adenocarcinoma is primarily surgical. The standard surgical technique is anal sacculectomy, which involves complete excision of the affected anal sac and the tumor. The procedure is performed under general anesthesia with the patient in sternal recumbency with the hindquarters elevated. A circumferential incision is made around the anal sac duct, and blunt dissection is used to isolate the anal sac from the surrounding tissues, taking care to avoid damage to the anal sphincter and rectum. The anal sac is removed en bloc with the tumor. If the tumor is large or invasive, a more extensive resection may be required, including partial anal sphincterectomy or rectal resection. Regional lymph nodes (iliosacral) should be assessed and removed if enlarged or metastatic. This may require a separate abdominal approach (celiotomy) for lymphadenectomy. In cases with extensive lymph node involvement, a combination of surgery and radiation therapy may be recommended. Adjunctive chemotherapy (e.g., carboplatin, mitoxantrone) may be used for metastatic disease or incompletely excised tumors. Medical management of hypercalcemia includes aggressive fluid therapy (0.9% NaCl), furosemide (2 mg/kg IV q8h), and prednisone (1-2 mg/kg PO q12h) if the tumor is not immediately resectable. Bisphosphonates (e.g., pamidronate 1-2 mg/kg IV) may be used for refractory hypercalcemia. Postoperative pain management includes opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h) and NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h) after renal function is confirmed.

The prognosis for anal sac adenocarcinoma is variable and depends on several factors. Dogs with small tumors (<2 cm) and no lymph node metastasis at the time of surgery have a good prognosis, with median survival times exceeding 3 years. The presence of lymph node metastasis reduces the median survival time to approximately 12-18 months, even with aggressive treatment. Hypercalcemia at presentation is a negative prognostic indicator, with median survival times of 6-12 months. Histologic features such as high mitotic index and nuclear atypia are associated with a poorer prognosis. Complete surgical excision with clean margins is associated with a lower recurrence rate. Incompletely excised tumors have a high rate of local recurrence. Dogs that undergo lymphadenectomy for metastatic lymph nodes may have improved survival compared to those with unresectable metastasis. Overall, the 1-year survival rate is approximately 70%, and the 2-year survival rate is approximately 40%. Regular monitoring for recurrence and metastasis is essential.

Postoperative follow-up for anal sac adenocarcinoma should include: 1) Immediate postoperative care: Monitor for complications such as hemorrhage, infection, and fecal incontinence. Suture removal from the perianal skin is typically performed 10-14 days after surgery. 2) Serial physical examinations: Recheck examinations should be performed every 3 months for the first year, then every 6 months thereafter. Digital rectal palpation should be performed to assess for local recurrence and sublumbar lymphadenopathy. 3) Serum biochemistry: Monitor serum calcium levels every 3-6 months to detect recurrence of hypercalcemia, which may indicate tumor recurrence or metastasis. 4) Thoracic radiographs: Repeat thoracic radiographs every 3-6 months to screen for pulmonary metastasis. 5) Abdominal ultrasound: Repeat abdominal ultrasound every 3-6 months to evaluate sublumbar lymph nodes and other abdominal organs. 6) Activity restriction: Restrict activity for 2-4 weeks postoperatively to allow proper healing. 7) Physical therapy: May be beneficial for patients with fecal incontinence to strengthen the anal sphincter. 8) Long-term monitoring: Continue monitoring for at least 2-3 years, as late recurrence and metastasis can occur.

Clinical Pearls: 1) Always perform a digital rectal examination in any dog presenting with perianal signs or hypercalcemia. 2) Preoperative measurement of ionized calcium is essential for accurate assessment of hypercalcemia. 3) When performing anal sacculectomy, use a combination of sharp and blunt dissection to stay in the correct tissue plane and avoid damage to the anal sphincter. 4) If the tumor is adhered to the rectum, consider a rectal pull-through or partial rectal resection to achieve clean margins. 5) Always evaluate the sublumbar lymph nodes preoperatively with ultrasound and FNA, as metastasis is common. 6) In cases of hypercalcemia, stabilize the patient with IV fluids and diuretics before surgery to reduce anesthetic risk. 7) Consider adjunctive radiation therapy for incompletely excised tumors or metastatic lymph nodes. Pitfalls: 1) Failure to recognize hypercalcemia preoperatively can lead to anesthetic complications and renal failure. 2) Incomplete excision of the anal sac can lead to local recurrence. 3) Damage to the anal sphincter during surgery can result in fecal incontinence, which is a significant complication. 4) Missing lymph node metastasis can lead to progressive disease. 5) Overlooking the possibility of bilateral anal sac tumors; always examine both anal sacs. 6) Using NSAIDs in hypercalcemic patients without first correcting renal function can exacerbate renal damage.

Perioperative antimicrobial prophylaxis: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative antimicrobials are not routinely indicated unless contamination occurs. Analgesia: Preoperative: Hydromorphone (0.05-0.1 mg/kg IV) or methadone (0.2-0.5 mg/kg IV). Intraoperative: Fentanyl CRI (5-10 mcg/kg/hr) or lidocaine CRI (25-50 mcg/kg/min) for multimodal analgesia. Postoperative: Hydromorphone (0.05-0.1 mg/kg IV q4-6h) or buprenorphine (0.01-0.02 mg/kg IV q6-8h) for 24-48 hours, then transition to oral opioids such as tramadol (2-5 mg/kg PO q8-12h) if needed. NSAIDs: Carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) after confirming normal renal function and hydration. Local anesthesia: Lumbosacral epidural with morphine (0.1 mg/kg) and bupivacaine (1 mg/kg) can provide excellent intraoperative and postoperative analgesia. Hypercalcemia management: 0.9% NaCl IV at 2-3 times maintenance (60-90 ml/kg/day) to promote calciuresis. Furosemide (2 mg/kg IV q8h) after rehydration. Prednisone (1-2 mg/kg PO q12h) if hypercalcemia persists. Pamidronate (1-2 mg/kg IV over 2-4 hours) for refractory hypercalcemia. Chemotherapy: Carboplatin (300 mg/m² IV q3-4 weeks) or mitoxantrone (5-6 mg/m² IV q3-4 weeks) for metastatic or incompletely excised tumors. Dosages should be adjusted based on renal function and hematologic monitoring.

Landmark studies on anal sac adenocarcinoma include: 1) Bennett et al. (2002) reported that dogs with ASAC and hypercalcemia had a median survival of 6 months compared to 18 months for normocalcemic dogs. 2) Williams et al. (2003) found that lymph node metastasis at diagnosis was associated with a 2-fold increased risk of death. 3) Polton et al. (2006) demonstrated that surgical excision with lymphadenectomy improved survival in dogs with metastatic lymph nodes. 4) A retrospective study by Emms (2005) showed that dogs with tumors <2 cm had a median survival of 3 years, while those with tumors >2 cm had a median survival of 1 year. 5) A study by Turek et al. (2003) evaluated the role of radiation therapy in incompletely excised tumors and found improved local control. 6) A consensus statement from the ACVS (2018) recommends staging with abdominal ultrasound and thoracic radiographs, and surgical excision with lymph node extirpation as the primary treatment. 7) A meta-analysis by Phelps et al. (2015) confirmed that hypercalcemia and lymph node metastasis are independent negative prognostic factors. 8) Recent studies have investigated the role of tyrosine kinase inhibitors (e.g., toceranib) in the treatment of ASAC, with some evidence of activity in metastatic disease. Overall, the evidence supports aggressive surgical resection and lymphadenectomy, with adjunctive therapies for advanced disease.